Coordinating Lipid Management in High and Very High Risk ASCVD

Published: 16 December 2021

  • Views:

    Views Icon 17503

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Join us for this live broadcast where faculty will ensure physicians based in Malaysia are aware of the importance of risk stratification in relation to secondary prevention and how this is dealt with in the recent ESC guidance and why it's important. The faculty will make a distinct comparison between the ESC guidelines and what the Malaysian guidelines say is central to this, including why is risk stratification important. 
 

In the second part of this broadcast, the faculty will outline how to implement lipid clinics and what the outcomes of these clinics are for patients. 
 

This programme is supported by an unrestricted educational grant by Novartis and being endorsed by the National Heart Association of Malaysia. 

This broadcast is supported by Novartis and endorsed by the National Heart Association of Malaysia

Learning Objectives

  • Stratify high and very high risk CVD patients to appropriate guideline directed medical therapy, taking into account local reimbursement and approval status
  • Demonstrate knowledge of current lipid-lowering targets for high and very high risk patients with established ASCVD via surrogate patient cases
  • Apply recent international guideline updates to daily practice
  • Discuss the advantages of coordinated, interdisciplinary care in ASCVD management
  • Recall the impact of specialist care on ASCVD outcomes

Target Audience

  • General Cardiologists

More from this programme

Part 1

Stratifying high and very high risk patients: Interpreting international guidance

In this session, Prof Kosh Ray will review the ESC guidance in dyslipidaemia and CV prevention. The presentation will be followed by a peer to peer discussion between Prof Kosh Ray and Dato' Dr Ali where they will analyse how the data presented and compare to the current Malaysian Guidelines.
1 session
Stratifying high and very high risk patients: Interpreting international guidance Watch now

Part 2

Achieving high quality care in specialist clinics

In this session, Dr Oliver Weingärtner will present on achieving high quality care in specialist clinics. Dr Weingärtner will provide a thorough overview of how lipid clinics enhance patient care and patient outcomes, and will showcase several case examples of an established clinic. This session will conclude with a discussion between Dr Weingärtner and and Dato' Dr Ali providing practical considerations for setting-up an established clinic.
1 session
Achieving high quality care in specialist clinics Watch now

Part 3

Q&A Session with audience

In this final session, the Experts will answer questions from the live audience.
1 session
Q&A Session with audience Watch now

Faculty Biographies

Muhamad Ali

Muhamad Ali

Dato’ Dr Muhamad Ali is a Senior Consultant Cardiologist and the Head of Department, Director of Invasive Cardiac Catheterization Laboratory in Hospital Pulau Pinang. He is also an Honorary Lecturer in Penang Medical College, Penang Internal Dental College, Penang Nursing College, and USM.  Dr Muhamad Ali is actively performing many interventional procedures and has trained a number of local and international cardiology fellows. He too is an avid researcher with involvement in numerous international and local trials. 

View full profile
Oliver Weingärtner

Oliver Weingärtner

Dr Oliver Weingärtner currently works at University Hospital Jena. As a certified interventional cardiologist and angiologist he has been trained in Internal Medicine, Cardiology, Angiology and Intensive Care Medicine Lipidologist (DGFF®)

Dr Weingärtner is the current President of the German Society of Lipidology. His research interests focus on cholesterol metabolism and cardiovascular risk.

View full profile